Trial reportBritish journal of cancer2003
A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.
Trial report in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Multi-center Study to Assess the Effect of Darbepoetin Alfa (Aranesp®) for the Treatment of Anemia in Patients With Advanced Hormone Independent Prostate Cancer and Anaemia
Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.
Who cites it
18 citing papers in PubMed, 7 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2022Pooled it
- Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis.Current oncology (Toronto, Ont.) · 2018Pooled it
- Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Erythropoietin or darbepoetin for patients with cancer.The Cochrane database of systematic reviews · 2012Pooled it
- Drug therapy for the management of cancer-related fatigue.The Cochrane database of systematic reviews · 2010Pooled it
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.British journal of cancer · 2010Pooled it
- Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.The Cochrane database of systematic reviews · 2009Pooled it
- Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.Clinical drug investigation · 2013Article
- Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009Article
- Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Therapeutics and clinical risk management · 2007Article
- Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2007Review
- Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Therapeutics and clinical risk management · 2006Article
- The relationship between patient knowledge of hemoglobin levels and health-related quality of life.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2006Article
- Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.Clinical drug investigation · 2006Article
- Single-dose darbepoetin administration to anemic preterm neonates.Journal of perinatology : official journal of the California Perinatal Association · 2005Article
- Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.Clinical drug investigation · 2005Article
- Management of anemia in patients with cancer.Current oncology reports · 2004Review
- Clinical and economic impact of epoetins in cancer care.PharmacoEconomics · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multicentre study evaluated the efficacy and safety of darbepoetin alpha administered weekly (QW), every 3 weeks (Q3W), and every 4 weeks (Q4W) to anaemic patients with cancer not concurrently receiving chemotherapy or radiotherapy. The QW portion (n=102) was an open-label, sequential, dose-escalation design; cohorts received darbepoetin alpha QW by subcutaneous (s.c.) injection at 0.5, 1.0, 2.25, or 4.5 micro g kg(-1) week(-1) for 12 weeks. The 12-week placebo-controlled, double-blind Q3W (6.75 micro g kg(-1)) and Q4W (6.75 or 10.0 micro g kg(-1)) schedules (n=86), which enrolled different patients, took place after the QW schedule and were followed by a 12-week, open-label phase. Patients were evaluated for change in haemoglobin end points and red blood cell transfusions, serum darbepoetin alpha concentration, and safety. Selected domains of health-related quality of life (HRQOL) were measured. With QW dosing, at least 70% of each cohort had a haemoglobin increase from baseline of > or =2 g dl(-1) or a concentration > or =12 g dl(-1) (haematopoietic response). In the 4.5 micro g kg(-1) QW cohort, all patients achieved a haematopoietic response (100%; 95% confidence interval (CI)=100, 100). In the Q3W and Q4W schedules, all cohorts had at least 60% of patients who achieved a haematopoietic response. Darbepoetin alpha effectively increases haemoglobin concentration when given QW, Q3W, or Q4W. Less-frequent administration may benefit patients with chronic anaemia of cancer and their caregivers alike.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.